DE69102265D1 - Immunkomplexe. - Google Patents

Immunkomplexe.

Info

Publication number
DE69102265D1
DE69102265D1 DE69102265T DE69102265T DE69102265D1 DE 69102265 D1 DE69102265 D1 DE 69102265D1 DE 69102265 T DE69102265 T DE 69102265T DE 69102265 T DE69102265 T DE 69102265T DE 69102265 D1 DE69102265 D1 DE 69102265D1
Authority
DE
Germany
Prior art keywords
substance
immune complexes
monoclonal antibody
biologically active
immune complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69102265T
Other languages
English (en)
Other versions
DE69102265T2 (de
Inventor
Naoru Hamaguchi
Jun Sato
Kazuhiro Doken
Susumu Iwasa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2287648A external-priority patent/JPH03279335A/ja
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of DE69102265D1 publication Critical patent/DE69102265D1/de
Application granted granted Critical
Publication of DE69102265T2 publication Critical patent/DE69102265T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69102265T 1990-02-06 1991-02-05 Immunkomplexe. Expired - Fee Related DE69102265T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2740790 1990-02-06
JP8018290 1990-03-28
JP2287648A JPH03279335A (ja) 1990-02-06 1990-10-24 免疫複合体
PCT/JP1991/000136 WO1991012022A1 (en) 1990-02-06 1991-02-05 Immune complexes

Publications (2)

Publication Number Publication Date
DE69102265D1 true DE69102265D1 (de) 1994-07-07
DE69102265T2 DE69102265T2 (de) 1994-10-13

Family

ID=27285782

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69102265T Expired - Fee Related DE69102265T2 (de) 1990-02-06 1991-02-05 Immunkomplexe.

Country Status (6)

Country Link
EP (1) EP0514544B1 (de)
JP (1) JP3260364B2 (de)
AT (1) ATE106251T1 (de)
CA (1) CA2073964A1 (de)
DE (1) DE69102265T2 (de)
WO (1) WO1991012022A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ263102A (en) * 1993-03-19 1997-05-26 Immunex Corp Pharmaceutical compositions comprising a ligand protein such as interleukin-4 and a soluble receptor protein that binds thereto
EP0975368A1 (de) * 1997-02-19 2000-02-02 Centocor, Inc. Arzneimittel mit verzögerter abgabe und zusammensetzung dafür

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
IE63847B1 (en) * 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers

Also Published As

Publication number Publication date
ATE106251T1 (de) 1994-06-15
EP0514544B1 (de) 1994-06-01
EP0514544A1 (de) 1992-11-25
CA2073964A1 (en) 1991-08-07
JP3260364B2 (ja) 2002-02-25
WO1991012022A1 (en) 1991-08-22
JPH06509541A (ja) 1994-10-27
DE69102265T2 (de) 1994-10-13

Similar Documents

Publication Publication Date Title
LV10178A (lv) Fiziologiski saderigu glabajot stabilu cilveka olbaltumvielu preparatu iegusanas panemiens
DE68919146D1 (de) Ausgewählte Stämme von Lactobacillus enthaltende pharmazeutische Zusammensetzungen.
FI843930L (fi) Maerkta konjugat av metalltionein och maolsoekande biologiskt aktiva molekyler.
CA2093928A1 (en) Monoclonal antibodies for detection and treatment of cancer
FI950062A (fi) Proteiinien foroaktivaatio konjugaatiotarkoituksia varten
SE8605295D0 (sv) Monoclonal antibodies cross-reactive and crossprotective against p. aeruginosa serotypes
IT7928370A0 (it) Procedimento per determinare l'emoglobina glicosilata in campioni di sangue.
NZ221440A (en) Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections
PL335752A1 (en) Anti-fas antibodies
IT1116032B (it) Composizione e procedimento per la determinazione della concentrazione del glucosio in fluidi corporei
DK403384A (da) Enteralt effektivt, biologisk aktivt peptid- eller proteinmiddel ogfremgangsmaader til fremstilling deraf
SE8002469L (sv) Forfarande och reagens for bestemning av hemoglobinhalten i blod
ATE106251T1 (de) Immunkomplexe.
EP0339163A3 (en) Monoclonal antibodies specific for hiv and hybridomas for their production
NO981454D0 (no) Anti-FAS-antistoffer
KR870700023A (ko) 녹농균의 E8Ag항원 및 그것에 대한 모노클로날 항체및 하이브리도마
ATE106205T1 (de) Pflegeset insbesondere für den reisebedarf.
JPS6461499A (en) Monoclonal antibody to human papilloma viruses 16 type e7 protein, and production and use thereof
DK0535347T3 (de)
IL84040A0 (en) Monoclonal antibodies against ifn-omega,their preparation and their use in the purification and detection of ifn-omega
IT9041599A0 (it) Anticorpo monoclonale che inibisce l'azione biologica del fattore piastrinico 4
NL188891C (nl) Farmaceutisch preparaat met bloeddrukverlagende werking dat co-dergocrine en nog een actief materiaal bevat.
DE69110067D1 (de) Monoklonale Antikörper gegen nicht-A 1C glykosyliertes Hämoglobin.
ES2063455T3 (es) Nueva forma unitaria, solida y porosa que comprende particulas en forma de perlas asi como su preparacion.
FR2654343B1 (fr) Utilisation d'un polypeptide ayant l'activite de l'interferon gamma pour la preparation de compositions pharmaceutiques destinees au traitement de cancers primitifs de la plevre.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee